Filing Overview
Registrant: Upjohn Inc., a wholly owned Pfizer subsidiary that became part of the proposed Viatris combination. Form 8-K date: May 29, 2020; signed June 1, 2020. The filing reports amendments to agreements governing the combination of Pfizer’s Upjohn Business with Mylan.
Business Context and Reporting Period
On May 29, 2020, Pfizer, Upjohn, Mylan and affiliates entered into Amendment No. 1 to the Business Combination Agreement, while Pfizer and Upjohn entered into Amendment No. 2 to the Separation and Distribution Agreement. The transaction contemplated the separation of Pfizer’s primarily off-patent branded and generic established medicines business and its combination with Mylan.
Financial and Operating Metrics
The filing is transactional and does not provide revenue, profit, cash flow, margins, debt, liquidity, or other current-period financial metrics. It also does not present comparative financial results.
Material Changes Versus Prior Disclosure
- The closing of the combination may not occur before October 1, 2020, unless Mylan and Pfizer agree otherwise.
- The transaction’s outside date was extended to December 31, 2020.
- The parties expected closing during the fourth quarter of 2020.
- Mylan’s shareholder meeting to approve matters related to the transaction was scheduled for June 30, 2020.
Outlook, Risks, and Contingencies
Regulatory review delays, including delays related to the COVID-19 pandemic, were cited as a reason for the amended timing. Completion remained subject to regulatory approvals, Mylan shareholder approval, satisfaction or waiver of other closing conditions, and the parties’ ability to complete the separation and combination.
Highlighted risks included COVID-19 effects; failure to obtain approvals; tax and accounting uncertainties; integration difficulty and costs; failure to achieve expected synergies; customer disruption and employee retention; liquidity and financing; manufacturing and supply-chain issues; litigation and government investigations; intellectual-property and product-launch risks; competition; pricing and reimbursement uncertainty; and changes in economic, regulatory, or market conditions.
The filing contains forward-looking statements regarding transaction timing, benefits, synergies, future operations, capital allocation, debt ratios, dividends, and financial performance. The parties stated that they undertook no obligation to update those statements except as required by law.
Investor Verification Items
- Verify the final closing date and whether the transaction satisfied all regulatory and shareholder conditions.
- Review Amendment No. 1 to the Business Combination Agreement and Amendment No. 2 to the Separation and Distribution Agreement, filed as Exhibits 2.1 and 2.2.
- Review subsequent SEC filings for changes to transaction terms, financing, tax treatment, accounting treatment, and expected synergies.
- Confirm the effectiveness and contents of the Form 10, the Form S-4, the prospectus, and Mylan’s proxy materials.
- Assess the COVID-19 impact and other identified risks using later financial statements and SEC filings.